These inorganic polyphosphate salts all function as chelating agents in cosmetic formulations. In addition, Sodium Metaphosphate functions as an oral care agent, Sodium Trimetaphosphate as a buffering agent, and Sodium Hexametaphosphate as a corrosion inhibitor. Only Sodium Hexametaphosphate is currently reported to be used. Although the typical concentrations historically have been less than 1%, higher concentrations have been used in products such as bath oils, which are diluted during normal use. Sodium Metaphosphate is the general term for any polyphosphate salt with four or more phosphate units. The four-phosphate unit version is cyclic, others are straight chains. The hexametaphosphate is the specific six-chain length form. The trimetaphosphate structure is cyclic. Rats fed 10% Sodium Trimetaphosphate for a month exhibited transient tubular necrosis; rats given 10% Sodium Metaphosphate had retarded growth and those fed 10% Sodium Hexametaphosphate had pale and swollen kidneys. In chronic studies using animals, growth inhibition, increased kidney weights (with calcium deposition and desquamation), bone decalcification, parathyroid hypertrophy and hyperplasia, inorganic phosphaturia, hepatic focal necrosis, and muscle fiber size alterations. Sodium Hexametaphosphate was a severe skin irritant in rabbits, whereas a 0.2% solution was only mildly irritating. A similar pattern was seen with ocular toxicity. These ingredients were not genotoxic in bacterial systems nor were they carcinogenic in rats. No reproductive or developmental toxicity was seen in studies using rats exposed to Sodium Hexametaphosphate or Sodium Trimetaphosphate. In clinical testing, irritation is seen as a function of concentration; concentrations as high as 1% produced no irritation in contact allergy patients. Because of the corrosive nature of Sodium Hexametaphosphate, it was concluded that these ingredients could be used safely if each formulation was prepared to avoid skin irritation; for example, low concentration in a leave-on product or dilution of a higher concentration as part of product usage.
References
1.
British Industrial Biological Research Association (BIBRA) Working Group.1964. Summaries of toxicological data: Toxicity studies on phosphates. Food Cosmet. Toxicol.2:147–154.
2.
Budavari, S., ed. 1989. The Merck index: An encyclopedia of chemicals, drugs, and biologicals, 11th ed., 1364, 1367, 1370. Rahway, NJ: Merck & Co.
3.
Chemline. 1996. Sodium Metaphosphate entry. Chemline database. Bethesda, MD: National Library of Medicine (NLM).
4.
Cosmetic, Toiletry, and Fragrance Association (CTFA).1997. Brief perspective on lead. Correspondence from G. N. McEwen, dated 2–4–97. (1 page.)2
5.
Daston, G. P., and F. E. Freeberg. 1991. Ocular irritation testing. In Dermal and ocular toxicology: Fundamentals and methods, ed. D. W. Hobsen, 509–539. Boca Raton, FL: CRC Press.
6.
Datta, P. K., A. C. Frazer, M. Sharratt, and H. G. Sammons. 1962. Biological effects of food additives. II. Sodium pyrophosphate. J. Sci. Food. Agriculture13:556–566.
7.
de Groot, A. C.1994. Patch testing: Test concentrations and vehicles for 3700 chemicals, 2nd ed., 11, 244. Amsterdam: Elsevier.
8.
Dymsza, H. A., G. Reussner, Jr., and R. Thiessen, Jr. 1959. Effect of normal and high intakes of orthophosphate and metaphosphate in rats. J. Nutr.69:419–428.
9.
Felts, J. M., and D. A. W. Bucks. 1981. Selective release of extrahepatic lipoprotein lipase by polymetaphosphate. Biochem. Biophys. Res. Commun.102:1034–1040.
10.
Fingerhut, M., F. Ruf, and K. Lang. 1965. Zur Frage der Resorption von Polyphosphaten. Klin. Wochensch.43:956–957.
11.
Finn, S. B., R. A. Frew, R. Leibowitz, W. Morse, L. Manson-Hing, and J. Brunelle. 1978. The effect of sodium trimetaphosphate (TMP) as a chewing gum additive on caries increments in children. J. Am. Dent. Assoc.96:651–655.
12.
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO).1996. Summary of evaluations performed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), s-17. USA: International Life Sciences Institute.
13.
Food and Drug Administration (FDA).1975. Evaluation of the health aspects of phosphates as food ingredients. NTIS document no. PB-262–651. Springfield, VA: NTIS.
14.
FDA.1984. Cosmetic product formulation and frequency of use data. FDA database. Washington, DC: FDA.
15.
FDA.1998. Frequency of use of cosmetic ingredients. FDA database. Washington, DC: FDA.
16.
Food and Drug Research Laboratories, Inc. (FDRL).1973. Initial submission: Evaluation of dermal effects of Erionyl Black GD in humans with cover letter dated 10–09–92 (Ciba-Geigy Corp.). NTIS document no. OTS0571841.
17.
FDRL.1974a. Approximate acute LD50 in mice and rats of Sodium Hexametaphosphate. Submitted by FDA in response to an FOI request—1997. (4 pages.)2
18.
FDRL.1974b. Teratologic evaluation of FDA 73–3 (Sodium Hexametaphosphate) in rats and mice—Final report. NTIS document no. PB-245535.
19.
Gosselin, R. E., and R. Megirian. 1955. The influence of chain length on the metabolic fate of condensed phosphates. J. Pharmacol. Exp. Ther.115:402–407.
20.
Gosselin, R. E., A. Rothstein, G. J. Miller, and H. L. Berke. 1952. The hydrolysis and excretion of polymeric phosphate. J. Pharmacol. Exp. Ther.106:180–192.
21.
Gosselin, R. E., R. P. Smith, and H. C. Hodge. 1984. Clinical toxicology of commercial products, 5th ed., 11–121. Baltimore, MD: Williams & Wilkins.
22.
Gosselin, R. E., C. S. Tidball, R. Megirian, E. A. Maynard, W. L. Downs, and H. C. Hodge. 1953. Metabolic acidosis and hypocalcemia as toxic manifestations of polymeric phosphates. J. Pharmacol. Exp. Ther.108:117–127.
23.
Grant, J., ed. 1972. Hackh's chemical dictionary4th ed., 125, 619, 679. New York: McGraw-Hill.
24.
Hazardous Substances Data Base.1996. Sodium Metaphosphate and Sodium Hexametaphosphate entries. Hazardous Substances Data Base database. Bethesda, MD: NLM.
25.
Irving, J. T., D. Schibler, and H. Fleisch. 1966. Bone formation in normal and vitamin D-treated rachitic rats during the administration of polyphosphates. Proc. Soc. Exp. Biol. Med.123:332–335.
26.
Ishidate, M., Jr., T. Sofuni, K. Yoshikawa, et al. 1984. Primary mutagenicity screening of food additives currently used in Japan. Food Chem. Toxicol.22:623–626.
27.
Jen, C. M. C., and L. A. Shelef. 1986. Factors affecting sensitivity of Staphylococcus aureus 196E to polyphosphates. Appl. Environ. Microbiol.52:842–846.
28.
Krishnarao, G. V. G., and H. H. Draper. 1972. Influence of dietary phosphate on bone resorption in senescent mice. J. Nutr.102:1143–1146.
29.
Laflamme, G. H., and J. Jowsey. 1972. Bone and soft tissue changes with oral phosphate supplements. J. Clin. Invest.51:2834–2840.
30.
Lauersen, F.1953. Über gensundheitliche Bedenken bei der Verwendung von Phosphorsäure und primärem Phosphat in Erfrischungsgetränken. Z. Lebensm. Unter Forsch.96:418–440.
31.
Leichsenring, J. M., L. M. Norris, S. A. Lamison, E. D. Wilson, and M. B. Patton1951. The effect of level of intake on calcium and phosphorus metabolism in college women. J. Nutr.45:407–418.
32.
Lewis, R. J., Sr. 1997. Hawley's condensed chemical dictionary, 13th ed., 1021. New York: John Wiley & Sons.
33.
Lewis, R. J., Sr. 1993. Hazardous chemicals desk reference, 3rd ed., 1027, 1160. New York: Van Nostrand Reinhold.
34.
Lewis, R. L.2000. Sax's dangerous properties of industrial materials, 5th ed., Entries SII500, SHM500, and SKM500. New York: John Wiley & Sons.
35.
Li, A. P., and C. A. Myers. 1988. In vitro evaluation of the cytotoxic potential of a novel man-made fiber, calcium sodium metaphosphate fiber (phosphate fiber). Fundam. Appl. Toxicol.11:21–28.
36.
Litton Bionetics, Inc.1975. Mutagenic evaluation of compound FDA 73–3, Sodium Hexametaphosphate. NTIS Document No. PB-245486.
37.
Malm, O. J.1953. On phosphates and phosphoric acid as dietary factors in the calcium balance of man. Scand. J. Clin. Lab. Invest.5:75–84.
Nair, R. S., F. R. Johannsen, H. F. Bolte, P. E. Newton, and W. E. Rinehart. 1992. Toxicity of calcium sodium metaphosphate fiber. II. Chronic inhalation and oncogenicity study. Fundam. Appl. Toxicol.19:79–90.
40.
National Academy of Sciences (NAS).1996. Food Chemicals Codex, 4th ed., 375–376. Washington, DC: National Academy Press.
41.
Nelson, M. F., R. E. Melton, J. R. Van Wazer, 1975. Sodium trimetaphosphate as a bone-imaging agent. I. Animal studies. J. Nucl. Med.16:1043–1048.
42.
Nikitakis, J. M., and G. N. McEwen, Jr., eds. 1990a. CTFA compendium, of cosmetic ingredient composition—specifications.Washington, DC: CTFA.
43.
Nikitakis, J. M., and G. N. McEwen Jr., eds. 1990b. CTFA compendium of cosmetic ingredient composition—descriptions II.Washington, DC: CTFA.
44.
Nordbø, H., G. Rølla, and P. Gjermo. 1980. The effect of chelating agents on plaque. J. Dent. Res.59:77–78.
45.
Omoto, M., T. Imai, M. Motegi, and T. Harada. 1986. Effects of condensed phosphate as a food additive on the liver, kidneys, muscles, and bones of the mouse. Toxicol. Lett. (Amst)31(suppl.):57.
46.
Registry of Toxic Effects of Chemical Substances (RTECS).1995. Sodium Hexametaphosphate entry. RTECS database. Bethesda, MD: NLM.
47.
Reiss, E., J. M. Canterbury, M. A. Bercovitz, and E. L. Kaplan. 1970. The role of phosphate in the secretion of parathyroid hormone in man. J. Clin. Invest.49:2146–2149.
48.
Rothschild, D. L., Jr. 1990. The food chemical news guide to the current status of food additives and color additives, 416.3. Washington, DC: Food Chemical News.
49.
Saxton, J. A., Jr., and G. H. Ellis. 1941. Effects of long-continued ingestion of sodium phosphate upon the parathyroids, kidneys, and bones of mature rats. Am. J. Pathol.17:590.
50.
Schibler, D., R. G. G. Russell, and H. Fleisch. 1968. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin. Sci.35:363–372.
51.
Seward, R. A., C. F. Lin, and N. Melachouris. 1986. Heat-sensitization of Salmonella by polyphosphates. J. Food Sci.51:471–473, 476.
52.
Sie, T. L., H. H. Draper., and R. R. Bell. 1974. Hypocalcemia, hyperparathyroidism, and bone resorption in rats induced by dietary phosphate. J. Nutr.104:1195–1201.
53.
Stauffer Chemical Company.1971. Initial submission: Rabbit eye irritant classification study with Sodium Hexametaphosphate, with cover letter dated 08–28–92. (ICI Americas, Inc.) NTIS Document No. OTS0545336.
54.
Stauffer Chemical Company.1972. Initial submission: Primary skin irritation of Sodium Hexametaphosphate, Powdered, in rabbits, with cover letter dated 10–16–92. (Rhone-Poulenc, Inc.) NTIS Document No. OTS0555931.
55.
Stookey, G. K., J. M. Warrick., and L. L. Miller. 1995. Effect of sodium hexametaphosphate on dental calculus in dogs. Am. J. Vet. Res.56:913–18.
56.
United States Department of Agriculture (USDA).1982. Meat and poultry products; Phosphates and Sodium Hydroxide. Final rule. Fed. Registrar47:10779–10785.
57.
Vaara, M.1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev.56:395–411.
58.
Water Quality Association (WQA).1995. WQA glossary of terms. Internet. http://www.wqa.org/WQIS/Glossary
59.
Wenninger, J. A., R. C. Canterbery, and G. N. McEwen, Jr., eds. 2000. International cosmetic ingredient dictionary and handbook, 8th ed., Vol. 2, 1360–1361, 1376, 1402. Washington, DC: CTFA.
60.
Whitford, D., D. W. Concar, and R. J. P. Williams. 1991. The promotion of self-association of horse-heart cytochrome c by hexametaphosphate anions. Eur. J. Biochem.199:561–568.
61.
World Health Organization (WHO).1964. Specifications for the identity and purity of food additives and their toxicological evaluation: Emulsifiers, stabilizers, bleaching and maturing agents. WHO Tech. Rep. Ser. No. 281. Geneva: WHO.
